 |
|
|
|
|
|
 Introduction
Descriptions
Synonyms
Image Bank
Lecture Bank
Video Bank
Introduction
Medical
Veterinary
Environmental
Industrial
Agricultural
Introduction
Susceptibility
MIC Database
Procedures
Histopathology
Introduction
Abbreviations
Links
CME
Conference
Highlights
Bibliography
Glossary
Good Books
Events Calendar
Introduction
Our Mission
Editorial Board
Editorial Staff
Supporters
Contributors
Legal Stuff
Privacy Policy
Kudos
Introduction
Descriptions
Synonyms
Image Bank
Lecture Bank
Video Bank
This page updated:
1/27/2007 9:23:00 AM
DoctorFungus - All Rights Reserved
© 2007 Copyright
& Privacy Policy
Site built and designed for doctorfungus by Webillustrated
|
 |
 |
|
You are here:
Mycoses >
|
Navigate this section from here:
|
|
Chromoblastomycosis
Chromomycosis
Chromoblastomycosis is a chronic localized infection of the skin and subcutaneous tissue that follows the traumatic implantation of the etiologic agent. The lesions are verrucoid, ulcerated, and crusted, and may be flat or raised 1-3 cm. Satellite lesions may develop following autoinoculation and by lymphatic spread to adjacent areas. The mycosis usually remains localized with extensive keloid formation. After many years, the lesions may resemble the head of a cauliflower [1485]. Many different fungi cause this disease. The disease takes its common name from the fact that most of the etiologic agents are dark-walled. Some of the causative agents (e.g., Fonsecaea pedrosoi and Phialophora verrucosa may disseminate to the brain [2093]. Elephantiasis and lymphatic stasis can occur as a result of secondary infections [692].
- cicatricial
- nodular
- plaque
- tumorous
- verrucous
The infection usually remains localized, but hematogenous dissemination in the immunosuppressed host has been rarely reported with a grave prognosis [1388]. Early stages of chromoblastomycosis are treated with surgical excision, electrodesiccation, cryosurgery or topical antifungals [1797]. Thiabendazole, 5-fluorocytosine, and amphotericin B have all been used topically. Advanced cases may require systemic treatment for long periods of time. Itraconazole and terbinafine are the drugs of choice [287, 692, 1857]. Results with fluconazole have been dissapointing [589]. In vitro data is promising for voriconazole [1492].
The skin lesions show a hyperkeratous pseudoepitheliomatous hyperplasia and keratolytic microabscesses in the epidermis. Dematiaceous hyphae and sclerotic bodies are found in the stratum corneum, with essentially only sclerotic bodies found in the areas of dermal inflammation. The sclerotic bodies are round, thick-walled, muriform, chestnut brown, and 5-12 µm in diameter. Brain abscesses are typically multilocular and well demarcated with thick walls. Irregular dematiaceous hyphae are seen in these abscesses.
Superficial crusts mounted in 10% KOH contain dematiaceous, septate branching hyphae 2-5 µm in diameter. Pus and granulation tissue obtained by curettage, or biopsy specimens of the epidermis and subcutaneous tissues typically contain dematiaceous round, thick-walled, muriform, bodies 5-12 µm in diameter.
Inoculate the clinical specimens onto Sabouraud glucose agar and a medium containing cycloheximide, IMA or BHI agar with 10% sheep blood. Incubate at 30°C and discard negative cultures in 4 weeks.
Soil and woody plant material
PubMed
|
Fonsecaea pedrosoi sclerotic bodies in KOH preparation
|
|
|
References
287. Bonifaz, A., E. Martinez-Soto, E. Carrasco-Gerard, and J. Peniche. 1997. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int. J. Dermatol. 36:542-7.
589. Diaz, M., R. Negroni, F. Montero-Gei, L. G. Castro, S. A. Sampaio, D. Borelli, A. Restrepo, L. Franco, J. L. Bran, E. G. Arathoon, and et al. 1992. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis. 14 Suppl 1:S68-76.
692. Esterre, P., C. K. Inzan, E. R. Ramarcel, A. Andriantsimahavandy, M. Ratsioharana, J. L. Pecarrere, and P. Roig. 1996. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 134 Suppl 46:33-6; discussion 40.
1388. Lundstrom, T. S., M. R. Fairfax, M. C. Dugan, J. A. Vazquez, P. H. Chandrasekar, E. Abella, and C. Kasten-Sportes. 1997. Phialophora verrucosa infection in a BMT patient. Bone Marrow Transplant. 20:789-91.
1485. McGinnis, M. R. 1983. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 8:1-16.
1492. McGinnis, M. R., and L. Pasarell. 1998. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. Antimicrob. Agents Chemother. 36:2353-2355.
1797. Pimentel, E. R., L. G. Castro, L. C. Cuce, and S. A. Sampaio. 1989. Treatment of chromomycosis by cryosurgery with liquid nitrogen: a report on eleven cases. J Dermatol Surg Oncol. 15:72-7.
1857. Queiroz-Telles, F., K. S. Purim, J. N. Fillus, G. F. Bordignon, R. P. Lameira, J. Van Cutsem, and G. Cauwenbergh. 1992. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int. J. Dermatol. 31:805-12.
2093. Shimosaka, S., and S. Waga. 1983. Cerebral chromoblastomycosis complicated by meningitis and multiple fungal aneurysms after resection of a granuloma. Case report. J Neurosurg. 59:158-61.
|
|
|
 |
 |
Home |
Image Bank |
Lecture Bank |
Knowledgebase |
Site Map |
Contact Us |
The Fungi |
Mycoses |
Drugs |
Laboratory |
Education & Tools |
About Us
|
|
|
|